RETROVIRAL NUCLEIC MATERIAL AND NUCLEOTIDE FRAGMENTS, IN PARTICULAR ASSOCIATED WITH MULTIPLE SCLEROSIS AND/OR RHEUMATOID ARTHRITIS, FOR DIAGNOSTIC, PROPHYLACTIC AND THERAPEUTIC USES
The following are claimed: (1) isolated or purified nucleic acid material comprising a nucleotide sequence selected from (i) the 310 bp, 635 bp, 1481 bp, 1329 bp, 1511 bp, 764 bp, 800 bp sequences given in the specification; (ii) sequences complementary to the sequences of (i); and (iii) sequences e...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre ; ger |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | KOMURIAN-PRADEL, FLORENCE MALLET, FRANCOIS MANDRAND, BERNARD OTT, CATHERINE BEDIN, FREDERIC SODOYER, MIREILLE PERRON, HERVE PARAHNOS-BACCALA, GLAUCIA |
| description | The following are claimed: (1) isolated or purified nucleic acid material comprising a nucleotide sequence selected from (i) the 310 bp, 635 bp, 1481 bp, 1329 bp, 1511 bp, 764 bp, 800 bp sequences given in the specification; (ii) sequences complementary to the sequences of (i); and (iii) sequences equivalent to the sequences of (i) and (ii), especially sequences having at least 50%, preferably at least 70%, homology with the sequences of (i) or (ii) for any stretch of 100 contiguous monomers; (2) isolated or purified nucleic acid material encoding a polypeptide having at least 50%, preferably at least 70%, homology with a peptide sequence selected from the 103, 77, 493, 162, 398 and 378 amino acid sequences given in the specification for any contiguous stretch of at least 30 amino acids; (3) retroviral nucleic acid material in which the pol gene comprises a nucleotide sequence identical or equivalent to the 310 bp sequence and its complements; (4) retroviral nucleic acid material in which the 5' end of the pol gene starts at nucleotide 1419 of the 1511bp sequence; (5) retroviral nucleic acid material in which the pol gene encodes a polypeptide having at least 50%, preferably at least 70%, homology with the 103 amino acid sequence for any contiguous stretch of at least 30 amino acids; (6) retroviral nucleic acid material in which the 3' end of the gag gene ends at nucleotide 1418 of 1511bp sequence; (7) retroviral nucleic acid material in which the env gene comprises a nucleotide sequence identical or equivalent to a sequence selected from 1481bp sequence and its complement; (8) retroviral nucleic acid material in which the env gene comprises a nucleotide sequence that starts at nucleotide 1 of the 1481 bp sequence and ends at nucleotide 233 of the 635 bp sequence; (9) retroviral nucleic acid material in which the env gene encodes a polypeptide having at least 50%, preferably at least 70%, homology with the 493 aa sequence for any contiguous stretch of at least 30 amino acids; (10) retroviral nucleic acid material in which the U3R region of the 3' LTR comprises a nucleotide sequence that ends at nucleotide 617 of the 635 bp sequence; (11) retroviral nucleic acid material in which the RU5 region of the 5' LTR comprises a nucleotide sequence that starts at nucleotide 755 of 1329 bp sequence and ends at nucleotide 337 of the 764 bp sequence or the 800 bp sequence; (12) retroviral nucleic acid material comprising a sequence that starts of nucleotide 755 of the |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP0996731B1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP0996731B1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP0996731B13</originalsourceid><addsrcrecordid>eNqNjkFKQ0EMht_GhVjvkANU2lJQuowzeZ3AvJkhySiuSpFxVdpCvZr3c6oewFX4_-T7yO3wJWSSX1gwQqouEjuY0Ei4F5j8b5mNPcEouJ0omc6BExQUY1cjCqBqdtwpD69sAaYajUsk0M5KVtarapEFJFDt-sweOh6Ejbtt7BvPuE1Zu3IORXIJbxFdTz9PWCDBQvWaq5LOhpuP_eHS7v_m3QAjmQsP7Xzatct5_96O7XNHZbnZPD6tV8-r9T9OvgEnO0rd</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>RETROVIRAL NUCLEIC MATERIAL AND NUCLEOTIDE FRAGMENTS, IN PARTICULAR ASSOCIATED WITH MULTIPLE SCLEROSIS AND/OR RHEUMATOID ARTHRITIS, FOR DIAGNOSTIC, PROPHYLACTIC AND THERAPEUTIC USES</title><source>esp@cenet</source><creator>KOMURIAN-PRADEL, FLORENCE ; MALLET, FRANCOIS ; MANDRAND, BERNARD ; OTT, CATHERINE ; BEDIN, FREDERIC ; SODOYER, MIREILLE ; PERRON, HERVE ; PARAHNOS-BACCALA, GLAUCIA</creator><creatorcontrib>KOMURIAN-PRADEL, FLORENCE ; MALLET, FRANCOIS ; MANDRAND, BERNARD ; OTT, CATHERINE ; BEDIN, FREDERIC ; SODOYER, MIREILLE ; PERRON, HERVE ; PARAHNOS-BACCALA, GLAUCIA</creatorcontrib><description>The following are claimed: (1) isolated or purified nucleic acid material comprising a nucleotide sequence selected from (i) the 310 bp, 635 bp, 1481 bp, 1329 bp, 1511 bp, 764 bp, 800 bp sequences given in the specification; (ii) sequences complementary to the sequences of (i); and (iii) sequences equivalent to the sequences of (i) and (ii), especially sequences having at least 50%, preferably at least 70%, homology with the sequences of (i) or (ii) for any stretch of 100 contiguous monomers; (2) isolated or purified nucleic acid material encoding a polypeptide having at least 50%, preferably at least 70%, homology with a peptide sequence selected from the 103, 77, 493, 162, 398 and 378 amino acid sequences given in the specification for any contiguous stretch of at least 30 amino acids; (3) retroviral nucleic acid material in which the pol gene comprises a nucleotide sequence identical or equivalent to the 310 bp sequence and its complements; (4) retroviral nucleic acid material in which the 5' end of the pol gene starts at nucleotide 1419 of the 1511bp sequence; (5) retroviral nucleic acid material in which the pol gene encodes a polypeptide having at least 50%, preferably at least 70%, homology with the 103 amino acid sequence for any contiguous stretch of at least 30 amino acids; (6) retroviral nucleic acid material in which the 3' end of the gag gene ends at nucleotide 1418 of 1511bp sequence; (7) retroviral nucleic acid material in which the env gene comprises a nucleotide sequence identical or equivalent to a sequence selected from 1481bp sequence and its complement; (8) retroviral nucleic acid material in which the env gene comprises a nucleotide sequence that starts at nucleotide 1 of the 1481 bp sequence and ends at nucleotide 233 of the 635 bp sequence; (9) retroviral nucleic acid material in which the env gene encodes a polypeptide having at least 50%, preferably at least 70%, homology with the 493 aa sequence for any contiguous stretch of at least 30 amino acids; (10) retroviral nucleic acid material in which the U3R region of the 3' LTR comprises a nucleotide sequence that ends at nucleotide 617 of the 635 bp sequence; (11) retroviral nucleic acid material in which the RU5 region of the 5' LTR comprises a nucleotide sequence that starts at nucleotide 755 of 1329 bp sequence and ends at nucleotide 337 of the 764 bp sequence or the 800 bp sequence; (12) retroviral nucleic acid material comprising a sequence that starts of nucleotide 755 of the 1329bp sequence and ends at nucleotide 617 of the 635bp sequence; (13) retroviral nucleic acid material as in (1)-(12) that is associated with at least one autoimmune disease such as multiple sclerosis or rheumatoid polyarthritis; (14) a nucleotide fragment comprising a nucleotide sequence as in (1); (15) a nucleotide fragment comprising a nucleotide sequence encoding a polypeptide as in (2); (16) a nucleic acid probe for detecting a retrovirus associated with multiple sclerosis and/or rheumatoid polyarthritis, capable of specifically hybridising to a fragment as in (14) or (15) belonging to the genome of the retrovirus; (17) a primer for amplifying RNA or DNA of a retrovirus associated with multiple sclerosis and/or rheumatoid polyarthritis, comprising a nucleotide sequence identical or equivalent to at least a portion of the nucleotide sequence of a fragment as in one of (8)-(11), especially a sequence having at least 50%, preferably at least 70%, homology with this portion for any stretch of 10 contiguous monomers; (18) RNA or DNA, especially a replication and/or cloning vector, comprising a genomic fragment of nucleic acid material as in one of (1)-(7) or a fragment as in (14) or (15); (19) a peptide encoded by any open reading frame belonging to a nucleotide fragment as in (14) or (15), especially a polypeptide, e.g. an oligopeptide, forming or comprising an antigenic determinant recognised by the sera of patients infected with the virus MSRV-1 and/or in whom the MSRV-1 virus has been reactivated.</description><edition>7</edition><language>eng ; fre ; ger</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS OR TEST PAPERS THEREFOR ; COMPOSITIONS THEREOF ; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROCESSES OF PREPARING SUCH COMPOSITIONS ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2005</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20050831&DB=EPODOC&CC=EP&NR=0996731B1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20050831&DB=EPODOC&CC=EP&NR=0996731B1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KOMURIAN-PRADEL, FLORENCE</creatorcontrib><creatorcontrib>MALLET, FRANCOIS</creatorcontrib><creatorcontrib>MANDRAND, BERNARD</creatorcontrib><creatorcontrib>OTT, CATHERINE</creatorcontrib><creatorcontrib>BEDIN, FREDERIC</creatorcontrib><creatorcontrib>SODOYER, MIREILLE</creatorcontrib><creatorcontrib>PERRON, HERVE</creatorcontrib><creatorcontrib>PARAHNOS-BACCALA, GLAUCIA</creatorcontrib><title>RETROVIRAL NUCLEIC MATERIAL AND NUCLEOTIDE FRAGMENTS, IN PARTICULAR ASSOCIATED WITH MULTIPLE SCLEROSIS AND/OR RHEUMATOID ARTHRITIS, FOR DIAGNOSTIC, PROPHYLACTIC AND THERAPEUTIC USES</title><description>The following are claimed: (1) isolated or purified nucleic acid material comprising a nucleotide sequence selected from (i) the 310 bp, 635 bp, 1481 bp, 1329 bp, 1511 bp, 764 bp, 800 bp sequences given in the specification; (ii) sequences complementary to the sequences of (i); and (iii) sequences equivalent to the sequences of (i) and (ii), especially sequences having at least 50%, preferably at least 70%, homology with the sequences of (i) or (ii) for any stretch of 100 contiguous monomers; (2) isolated or purified nucleic acid material encoding a polypeptide having at least 50%, preferably at least 70%, homology with a peptide sequence selected from the 103, 77, 493, 162, 398 and 378 amino acid sequences given in the specification for any contiguous stretch of at least 30 amino acids; (3) retroviral nucleic acid material in which the pol gene comprises a nucleotide sequence identical or equivalent to the 310 bp sequence and its complements; (4) retroviral nucleic acid material in which the 5' end of the pol gene starts at nucleotide 1419 of the 1511bp sequence; (5) retroviral nucleic acid material in which the pol gene encodes a polypeptide having at least 50%, preferably at least 70%, homology with the 103 amino acid sequence for any contiguous stretch of at least 30 amino acids; (6) retroviral nucleic acid material in which the 3' end of the gag gene ends at nucleotide 1418 of 1511bp sequence; (7) retroviral nucleic acid material in which the env gene comprises a nucleotide sequence identical or equivalent to a sequence selected from 1481bp sequence and its complement; (8) retroviral nucleic acid material in which the env gene comprises a nucleotide sequence that starts at nucleotide 1 of the 1481 bp sequence and ends at nucleotide 233 of the 635 bp sequence; (9) retroviral nucleic acid material in which the env gene encodes a polypeptide having at least 50%, preferably at least 70%, homology with the 493 aa sequence for any contiguous stretch of at least 30 amino acids; (10) retroviral nucleic acid material in which the U3R region of the 3' LTR comprises a nucleotide sequence that ends at nucleotide 617 of the 635 bp sequence; (11) retroviral nucleic acid material in which the RU5 region of the 5' LTR comprises a nucleotide sequence that starts at nucleotide 755 of 1329 bp sequence and ends at nucleotide 337 of the 764 bp sequence or the 800 bp sequence; (12) retroviral nucleic acid material comprising a sequence that starts of nucleotide 755 of the 1329bp sequence and ends at nucleotide 617 of the 635bp sequence; (13) retroviral nucleic acid material as in (1)-(12) that is associated with at least one autoimmune disease such as multiple sclerosis or rheumatoid polyarthritis; (14) a nucleotide fragment comprising a nucleotide sequence as in (1); (15) a nucleotide fragment comprising a nucleotide sequence encoding a polypeptide as in (2); (16) a nucleic acid probe for detecting a retrovirus associated with multiple sclerosis and/or rheumatoid polyarthritis, capable of specifically hybridising to a fragment as in (14) or (15) belonging to the genome of the retrovirus; (17) a primer for amplifying RNA or DNA of a retrovirus associated with multiple sclerosis and/or rheumatoid polyarthritis, comprising a nucleotide sequence identical or equivalent to at least a portion of the nucleotide sequence of a fragment as in one of (8)-(11), especially a sequence having at least 50%, preferably at least 70%, homology with this portion for any stretch of 10 contiguous monomers; (18) RNA or DNA, especially a replication and/or cloning vector, comprising a genomic fragment of nucleic acid material as in one of (1)-(7) or a fragment as in (14) or (15); (19) a peptide encoded by any open reading frame belonging to a nucleotide fragment as in (14) or (15), especially a polypeptide, e.g. an oligopeptide, forming or comprising an antigenic determinant recognised by the sera of patients infected with the virus MSRV-1 and/or in whom the MSRV-1 virus has been reactivated.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS OR TEST PAPERS THEREFOR</subject><subject>COMPOSITIONS THEREOF</subject><subject>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROCESSES OF PREPARING SUCH COMPOSITIONS</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2005</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjkFKQ0EMht_GhVjvkANU2lJQuowzeZ3AvJkhySiuSpFxVdpCvZr3c6oewFX4_-T7yO3wJWSSX1gwQqouEjuY0Ei4F5j8b5mNPcEouJ0omc6BExQUY1cjCqBqdtwpD69sAaYajUsk0M5KVtarapEFJFDt-sweOh6Ejbtt7BvPuE1Zu3IORXIJbxFdTz9PWCDBQvWaq5LOhpuP_eHS7v_m3QAjmQsP7Xzatct5_96O7XNHZbnZPD6tV8-r9T9OvgEnO0rd</recordid><startdate>20050831</startdate><enddate>20050831</enddate><creator>KOMURIAN-PRADEL, FLORENCE</creator><creator>MALLET, FRANCOIS</creator><creator>MANDRAND, BERNARD</creator><creator>OTT, CATHERINE</creator><creator>BEDIN, FREDERIC</creator><creator>SODOYER, MIREILLE</creator><creator>PERRON, HERVE</creator><creator>PARAHNOS-BACCALA, GLAUCIA</creator><scope>EVB</scope></search><sort><creationdate>20050831</creationdate><title>RETROVIRAL NUCLEIC MATERIAL AND NUCLEOTIDE FRAGMENTS, IN PARTICULAR ASSOCIATED WITH MULTIPLE SCLEROSIS AND/OR RHEUMATOID ARTHRITIS, FOR DIAGNOSTIC, PROPHYLACTIC AND THERAPEUTIC USES</title><author>KOMURIAN-PRADEL, FLORENCE ; MALLET, FRANCOIS ; MANDRAND, BERNARD ; OTT, CATHERINE ; BEDIN, FREDERIC ; SODOYER, MIREILLE ; PERRON, HERVE ; PARAHNOS-BACCALA, GLAUCIA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP0996731B13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2005</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS OR TEST PAPERS THEREFOR</topic><topic>COMPOSITIONS THEREOF</topic><topic>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROCESSES OF PREPARING SUCH COMPOSITIONS</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>KOMURIAN-PRADEL, FLORENCE</creatorcontrib><creatorcontrib>MALLET, FRANCOIS</creatorcontrib><creatorcontrib>MANDRAND, BERNARD</creatorcontrib><creatorcontrib>OTT, CATHERINE</creatorcontrib><creatorcontrib>BEDIN, FREDERIC</creatorcontrib><creatorcontrib>SODOYER, MIREILLE</creatorcontrib><creatorcontrib>PERRON, HERVE</creatorcontrib><creatorcontrib>PARAHNOS-BACCALA, GLAUCIA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KOMURIAN-PRADEL, FLORENCE</au><au>MALLET, FRANCOIS</au><au>MANDRAND, BERNARD</au><au>OTT, CATHERINE</au><au>BEDIN, FREDERIC</au><au>SODOYER, MIREILLE</au><au>PERRON, HERVE</au><au>PARAHNOS-BACCALA, GLAUCIA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>RETROVIRAL NUCLEIC MATERIAL AND NUCLEOTIDE FRAGMENTS, IN PARTICULAR ASSOCIATED WITH MULTIPLE SCLEROSIS AND/OR RHEUMATOID ARTHRITIS, FOR DIAGNOSTIC, PROPHYLACTIC AND THERAPEUTIC USES</title><date>2005-08-31</date><risdate>2005</risdate><abstract>The following are claimed: (1) isolated or purified nucleic acid material comprising a nucleotide sequence selected from (i) the 310 bp, 635 bp, 1481 bp, 1329 bp, 1511 bp, 764 bp, 800 bp sequences given in the specification; (ii) sequences complementary to the sequences of (i); and (iii) sequences equivalent to the sequences of (i) and (ii), especially sequences having at least 50%, preferably at least 70%, homology with the sequences of (i) or (ii) for any stretch of 100 contiguous monomers; (2) isolated or purified nucleic acid material encoding a polypeptide having at least 50%, preferably at least 70%, homology with a peptide sequence selected from the 103, 77, 493, 162, 398 and 378 amino acid sequences given in the specification for any contiguous stretch of at least 30 amino acids; (3) retroviral nucleic acid material in which the pol gene comprises a nucleotide sequence identical or equivalent to the 310 bp sequence and its complements; (4) retroviral nucleic acid material in which the 5' end of the pol gene starts at nucleotide 1419 of the 1511bp sequence; (5) retroviral nucleic acid material in which the pol gene encodes a polypeptide having at least 50%, preferably at least 70%, homology with the 103 amino acid sequence for any contiguous stretch of at least 30 amino acids; (6) retroviral nucleic acid material in which the 3' end of the gag gene ends at nucleotide 1418 of 1511bp sequence; (7) retroviral nucleic acid material in which the env gene comprises a nucleotide sequence identical or equivalent to a sequence selected from 1481bp sequence and its complement; (8) retroviral nucleic acid material in which the env gene comprises a nucleotide sequence that starts at nucleotide 1 of the 1481 bp sequence and ends at nucleotide 233 of the 635 bp sequence; (9) retroviral nucleic acid material in which the env gene encodes a polypeptide having at least 50%, preferably at least 70%, homology with the 493 aa sequence for any contiguous stretch of at least 30 amino acids; (10) retroviral nucleic acid material in which the U3R region of the 3' LTR comprises a nucleotide sequence that ends at nucleotide 617 of the 635 bp sequence; (11) retroviral nucleic acid material in which the RU5 region of the 5' LTR comprises a nucleotide sequence that starts at nucleotide 755 of 1329 bp sequence and ends at nucleotide 337 of the 764 bp sequence or the 800 bp sequence; (12) retroviral nucleic acid material comprising a sequence that starts of nucleotide 755 of the 1329bp sequence and ends at nucleotide 617 of the 635bp sequence; (13) retroviral nucleic acid material as in (1)-(12) that is associated with at least one autoimmune disease such as multiple sclerosis or rheumatoid polyarthritis; (14) a nucleotide fragment comprising a nucleotide sequence as in (1); (15) a nucleotide fragment comprising a nucleotide sequence encoding a polypeptide as in (2); (16) a nucleic acid probe for detecting a retrovirus associated with multiple sclerosis and/or rheumatoid polyarthritis, capable of specifically hybridising to a fragment as in (14) or (15) belonging to the genome of the retrovirus; (17) a primer for amplifying RNA or DNA of a retrovirus associated with multiple sclerosis and/or rheumatoid polyarthritis, comprising a nucleotide sequence identical or equivalent to at least a portion of the nucleotide sequence of a fragment as in one of (8)-(11), especially a sequence having at least 50%, preferably at least 70%, homology with this portion for any stretch of 10 contiguous monomers; (18) RNA or DNA, especially a replication and/or cloning vector, comprising a genomic fragment of nucleic acid material as in one of (1)-(7) or a fragment as in (14) or (15); (19) a peptide encoded by any open reading frame belonging to a nucleotide fragment as in (14) or (15), especially a polypeptide, e.g. an oligopeptide, forming or comprising an antigenic determinant recognised by the sera of patients infected with the virus MSRV-1 and/or in whom the MSRV-1 virus has been reactivated.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre ; ger |
| recordid | cdi_epo_espacenet_EP0996731B1 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR COMPOSITIONS THEREOF CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | RETROVIRAL NUCLEIC MATERIAL AND NUCLEOTIDE FRAGMENTS, IN PARTICULAR ASSOCIATED WITH MULTIPLE SCLEROSIS AND/OR RHEUMATOID ARTHRITIS, FOR DIAGNOSTIC, PROPHYLACTIC AND THERAPEUTIC USES |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T12%3A03%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KOMURIAN-PRADEL,%20FLORENCE&rft.date=2005-08-31&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP0996731B1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |